Thermo Fisher Scientific to Provide Antibody Publication Data on its Website

Thermo Fisher Scientific, the world leader in serving science, announced it has signed an agreement with BenchSci to utilize its proprietary machine learning platform to mine antibody data published in peer-reviewed scientific journals. The data and associated application information will be displayed on product-specific webpages to help scientists make informed decisions about the optimal antibodies to use in their experiments. Prior to the availability of the platform on Thermo Fisher’s site, researchers were forced to rely on scientific search engines, sift through numerous papers, then tab back and forth between the published studies and product websites. The process could take hours or even days but is now significantly reduced to minutes by extracting key information and figures from open- and closed-access papers.

An image gallery on Thermo Fisher’s relevant antibody product pages will incorporate data generated by BenchSci’s platform so visitors on the website can review both internal product development data and figures from peer-reviewed journals in one location. Additional published figures covering more antibodies will be added over time. Poor antibody specificity or application performance can significantly hinder the ability to obtain good results, which can cause critical research delays. Choosing wrong or underperforming antibodies result in a lack of reproducibility, wasted time and wasted resources. Researchers need antibodies that bind to the right target and work in their applications every time.

“Data is absolutely critical to ensuring that scientists can make high confidence decisions about what antibody reagent is likely to be most appropriate for their application of interest,” said Dara Wright, vice president and general manager of protein and cell analysis, Thermo Fisher Scientific. “Far too much time and money is wasted on the use of antibodies which don’t meet expectations. This new capability, coupled with our internal validation initiatives, is a meaningful step forward.” – Medical Buyer Bureau